Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
Healthy Volunteer
Type
Observational
Design
Observational Model: CohortTime Perspective: Prospective

Participation Requirements

Age
Between 18 years and 99 years
Gender
Both males and females

Description

Background: Adoptive T cell therapies are being used to treat patients with cancer and hematological malignancies. Some of these therapies require that the patients T cells be expanded over 100-fold. This cell expansion can be accomplished by culturing autologous T cells with peripheral blood mononu...

Background: Adoptive T cell therapies are being used to treat patients with cancer and hematological malignancies. Some of these therapies require that the patients T cells be expanded over 100-fold. This cell expansion can be accomplished by culturing autologous T cells with peripheral blood mononuclear cells (PBMCs) collected from healthy subjects. This process is known as the Rapid Expansion Protocol (REP) and makes use of pooled irradiated PBMCs from healthy subjects. Objectives: To provide a mechanism for the collection of PBMCs from healthy subjects to use for the expansion of autologous T cells from patients with cancer. To improve and develop new methods to isolate PBMCs and to expand T cells for adoptive cellular therapy. Eligibility: Subjects must be greater than or equal to 18 years old and able to provide informed consent Subjects must have adequate clinical parameters (all of the following): Afebrile (temperature less than or equal to 37.5 degree C) Systolic blood pressure less than or equal to 180 mmHg Diastolic blood pressure less than or equal to 100 mmHg Weight greater than or equal to 110 lbs Heart rate between 50-100 beats/minute Adequate bilateral antecubital venous access for a 2 arm apheresis procedure Females of child-bearing potential should not be pregnant Design: This protocol will provide a mechanism for banking frozen PBMCs that can be used for the expansion of clinical T cell therapies and for developing new expansion procedures. The PBMCs will be collected in the Dowling Apheresis Clinic and processed in the Cell Processing Section (CPS) Laboratory both of which are located in the Department of Transfusion Medicine (DTM), Clinical Center following their established procedures. After the PBMCs are collected and processed, they will be cryopreserved. When needed, they will be thawed in the Cell Processing Laboratory, irradiated, pooled and used for the expansion of patient T cells over 2 to 3 weeks. Up to 500 subjects for PBMC collection will be enrolled in this study.

Tracking Information

NCT #
NCT02821806
Collaborators
Not Provided
Investigators
Principal Investigator: Scott M Norberg, D.O. National Cancer Institute (NCI)